Workflow
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates
ACADACADIA Pharmaceuticals(ACAD) ZACKS·2025-05-07 22:41

Company Performance - Acadia Pharmaceuticals reported quarterly earnings of 0.11pershare,exceedingtheZacksConsensusEstimateof0.11 per share, exceeding the Zacks Consensus Estimate of 0.10 per share, and showing an increase from 0.10pershareayearago,representinga100.10 per share a year ago, representing a 10% earnings surprise [1] - The company posted revenues of 244.32 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.23%, and up from 205.83millionyear−over−year[2]−Overthelastfourquarters,AcadiahassurpassedconsensusEPSestimatesthreetimesandtoppedconsensusrevenueestimatesfourtimes[2]StockOutlook−Acadiashareshavedeclinedapproximately20.8205.83 million year-over-year [2] - Over the last four quarters, Acadia has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Outlook - Acadia shares have declined approximately 20.8% since the beginning of the year, compared to a 4.7% decline in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is 0.18 on revenues of 262.31million,andforthecurrentfiscalyear,itis262.31 million, and for the current fiscal year, it is 0.68 on revenues of $1.06 billion [7] - The estimate revisions trend for Acadia is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Acadia belongs, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]